October 26, 2015.
Writing for the pharmaviews.eu blog on Friday, Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), called for a global “charter” to ensure that new antibiotics will be administered in a controlled manner and at affordable prices.
The new approach must "include de-linking revenues from selling, at least outside the richer countries in Europe and North America", wrote Bergström. "What I mean is that pharma companies should not have an incentive to sell as much as they can. Somehow they have to be rewarded differently, such as through an advanced purchase commitment (such as real or virtual stock-piling), or with transferable rights, reflecting the voucher system that is prevalent in the US."
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.